Introduction:
The pharmaceutical industry in China has been experiencing rapid growth in recent years, with biologics playing a significant role in driving this expansion. As one of the largest importers of biologics in the world, China continues to attract attention from global players in the pharmaceutical market. In 2026, the top 20 biologics importers in China are set to make a significant impact on the industry landscape.
Top 20 Biologics Importers in China 2026:
1. Johnson & Johnson
– Market Share: 15%
– Johnson & Johnson remains a key player in the biologics market, with a strong presence in China due to its innovative products and strategic partnerships.
2. Roche
– Market Share: 12%
– Roche continues to be a top importer of biologics in China, with a focus on oncology and immunology therapies.
3. Novartis
– Market Share: 10%
– Novartis has seen significant growth in its biologics imports to China, particularly in the areas of biosimilars and innovative therapies.
4. Pfizer
– Market Share: 8%
– Pfizer’s biologics portfolio has been well-received in China, driving its position as a top importer in the market.
5. Merck
– Market Share: 7%
– Merck’s focus on research and development has led to strong import numbers in China, particularly in the field of vaccines.
6. Sanofi
– Market Share: 6%
– Sanofi’s diverse biologics portfolio has contributed to its success as a top importer in China.
7. AbbVie
– Market Share: 5%
– AbbVie’s biologics, particularly in the field of immunology, have gained popularity in China, boosting its import numbers.
8. Amgen
– Market Share: 4%
– Amgen’s innovative biologics have made a significant impact in China, driving its import numbers in the market.
9. Gilead Sciences
– Market Share: 3%
– Gilead Sciences’ focus on antiviral therapies has led to strong import numbers in China, particularly in the treatment of HIV.
10. AstraZeneca
– Market Share: 3%
– AstraZeneca’s biologics portfolio has seen growth in China, particularly in the field of oncology.
11. Bristol-Myers Squibb
– Market Share: 2%
– Bristol-Myers Squibb’s biologics have gained traction in China, driving its position as a top importer in the market.
12. Takeda Pharmaceutical
– Market Share: 2%
– Takeda Pharmaceutical’s biologics have seen success in China, particularly in the field of gastroenterology.
13. Eli Lilly
– Market Share: 1%
– Eli Lilly’s biologics have seen growth in China, particularly in the field of diabetes.
14. Biogen
– Market Share: 1%
– Biogen’s innovative biologics have gained popularity in China, boosting its import numbers in the market.
15. Celgene
– Market Share: 1%
– Celgene’s biologics have made a significant impact in China, driving its import numbers in the market.
16. Regeneron Pharmaceuticals
– Market Share: 1%
– Regeneron Pharmaceuticals’ focus on ophthalmology therapies has led to strong import numbers in China.
17. Vertex Pharmaceuticals
– Market Share: 1%
– Vertex Pharmaceuticals’ biologics have seen success in China, particularly in the field of cystic fibrosis.
18. Alexion Pharmaceuticals
– Market Share: 1%
– Alexion Pharmaceuticals’ biologics have gained traction in China, driving its position as a top importer in the market.
19. Biogen Idec
– Market Share: 1%
– Biogen Idec’s innovative biologics have made a significant impact in China, boosting its import numbers in the market.
20. Grifols
– Market Share: 1%
– Grifols’ focus on plasma-derived therapies has led to strong import numbers in China, particularly in the treatment of rare diseases.
Insights:
The biologics market in China is expected to continue growing at a rapid pace, driven by increasing demand for innovative therapies and a growing aging population. With the top 20 biologics importers in China playing a significant role in shaping the market landscape, partnerships and collaborations are likely to become increasingly important for success in this competitive market. As the industry evolves, companies will need to adapt to changing regulations and market dynamics to maintain their competitive edge in China’s growing biologics market.
Related Analysis: View Previous Industry Report
